Steve Harr, Sana CEO

As its next big bet, Sana inks long-term lease for man­u­fac­tur­ing site for next-gen cell ther­a­pies

A uni­corn mul­ti­ple times over, Sana Biotech­nol­o­gy hit Nas­daq run­ning in Feb­ru­ary with its next-gen cell ther­a­pies still months away from the clin­ic. Now, Sana is look­ing to the fu­ture once again and clear­ing out some el­bow room for its man­u­fac­tur­ing team.

Sana has en­tered a long-term lease to de­vel­op a 163,000-square-foot man­u­fac­tur­ing fa­cil­i­ty in Cal­i­for­nia to ad­vance its late-stage clin­i­cal de­vel­op­ment and ear­ly com­mer­cial launch­es.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.